Precipio Inc. (PRPO): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Brandmark of Precipio, Inc (PRPO)

Precipio, Inc. (PRPO) is managed by industry specialists focused on implementing patented developments with full expenditure transparency. The business generates revenue through the sale of reagents and the performance of high-precision blood analyses for oncology centers. This price chart illustrates the EV/EBITDA multiple, which currently stands at 139.94. High switching costs to alternative diagnostic systems and the unique IVCell technology firmly protect the issuer's market position.

Precipio, Inc - PRPO EV/EBITDA Multiple (period 11/23/2025 - 11/10/2026)

PRPO (precipiodx.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Precipio, Inc|PRPO - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Precipio Inc|PRPO - Business Value
- book value of equity indicators:
Book Value per Share Precipio|PRPO - Book Capitalization|Market Value to Book Value Ratio precipiodx.com|PRPO - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Precipio, Inc.|PRPO - Long-Term Liabilities to Capital|Short-Term Debt to Equity Precipio|PRPO - Company Total Debt Obligations|Debts to Book Capitalization Precipio Inc|PRPO - Long-Term Debt Volume|Company Short-Term Debt Precipio|Quick Liquidity precipiodx.com
- financial results and valuation multiples details:
PRPO - Profit After Tax|Expected Profit Precipio, Inc.|PRPO - Company Value to Net Income|Forward P/E Multiple Precipio, Inc.|PRPO - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Precipio Inc|PRPO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Precipio|PRPO - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months precipiodx.com|PRPO - Earnings per share trend in current year|Earnings growth forecast for next year Precipio, Inc.
Comprehensive company analysis:Precipio, Inc PRPO
Manufactured products of Precipio

Investors are assessing the potential of Precipio, Inc. (PRPO) through the ratio of enterprise value to EBITDA, which allows the valuation to be stripped of the impact of debt load. By analyzing the EV/EBITDA multiple of the business, one can determine whether the expansion of the ICE-Cold PCR platform within the cancer biopsy segment justifies the current capitalization or creates a risk of overvaluation should monetary policy shift.

Analysis of competing companies

EV/EBITDA Multiple CAI (Caris)|EV/EBITDA Multiple Guardant Corp GH|VCYT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELC (celcuity.com) - Enterprise Value to Operating Income Before Depreciation|GRAL: EV/EBITDA Multiple|Myriad Genetics Inc (MYGN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Castle Biosciences Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BNR|Enterprise Value to EBITDA Ratio VNRX (VolitionRx Limited)|BDSX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Check-Cap CHEK|Total Company Value to Operating Income Before Depreciation Ratio mainzbiomed.com (MYNZ)|OncoCyte Corp. - EV/EBITDA Multiple